Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma

Alon Harris, Oliver Arend, Larry Kagemann, Melanie Garrett, Hak Sung Chung, Bruce Martin

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The purpose of this study was to determine how a topical carbonic anhydrase inhibitor, dorzolamide, alters visual function and ocular blood flow in persons with normal-tension glaucoma. Eighteen normal tension glaucoma patients, after washout of other ocular medications, were treated for four weeks with 2% dorzolamide, three times daily. A control group of eleven other normal-tension glaucoma patients received placebo eye drops. Patients were studied before treatment, and after two and four weeks of treatment. Each study included assessment of central visual function (contrast sensitivity), intraocular pressure (IOP), and several aspects of ocular hemodynamics, including measures of retinal arteriovenous passage time, retinal arterial and venous diameters, and flow velocities in the ophthalmic, central retinal, and posterior ciliary arteries. Dorzolamide significantly reduced lOP at two and four weeks (each p<0.01), and at the same time increased contrast sensitivity at both three and six cycles per degree (each p<0.05). Neither of these variables changed significantly in the control group. Dorzolamide also accelerated retinal arteriovenous passage time of fluorescein dye, at constant retinal arterial and venous diameters (p<0.05), but failed to change flow velocities in any retrobulbar vessel. The ability of dorzolamide to improve contrast sensitivity in persons with normal-tension glaucoma may be related to either IOP reduction or altered ocular perfusion.

Original languageEnglish
Pages (from-to)189-197
Number of pages9
JournalJournal of Ocular Pharmacology and Therapeutics
Volume15
Issue number3
StatePublished - Jun 1999

Fingerprint

dorzolamide
Low Tension Glaucoma
Hemodynamics
Contrast Sensitivity
Intraocular Pressure
Ciliary Arteries
Carbonic Anhydrase Inhibitors
Control Groups
Aptitude
Ophthalmic Solutions
Fluorescein
Coloring Agents
Perfusion
Placebos

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Harris, A., Arend, O., Kagemann, L., Garrett, M., Chung, H. S., & Martin, B. (1999). Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. Journal of Ocular Pharmacology and Therapeutics, 15(3), 189-197.

Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. / Harris, Alon; Arend, Oliver; Kagemann, Larry; Garrett, Melanie; Chung, Hak Sung; Martin, Bruce.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 15, No. 3, 06.1999, p. 189-197.

Research output: Contribution to journalArticle

Harris, A, Arend, O, Kagemann, L, Garrett, M, Chung, HS & Martin, B 1999, 'Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma', Journal of Ocular Pharmacology and Therapeutics, vol. 15, no. 3, pp. 189-197.
Harris, Alon ; Arend, Oliver ; Kagemann, Larry ; Garrett, Melanie ; Chung, Hak Sung ; Martin, Bruce. / Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. In: Journal of Ocular Pharmacology and Therapeutics. 1999 ; Vol. 15, No. 3. pp. 189-197.
@article{5b1cd6b27ced4d3baa27fecd65fcda3c,
title = "Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma",
abstract = "The purpose of this study was to determine how a topical carbonic anhydrase inhibitor, dorzolamide, alters visual function and ocular blood flow in persons with normal-tension glaucoma. Eighteen normal tension glaucoma patients, after washout of other ocular medications, were treated for four weeks with 2{\%} dorzolamide, three times daily. A control group of eleven other normal-tension glaucoma patients received placebo eye drops. Patients were studied before treatment, and after two and four weeks of treatment. Each study included assessment of central visual function (contrast sensitivity), intraocular pressure (IOP), and several aspects of ocular hemodynamics, including measures of retinal arteriovenous passage time, retinal arterial and venous diameters, and flow velocities in the ophthalmic, central retinal, and posterior ciliary arteries. Dorzolamide significantly reduced lOP at two and four weeks (each p<0.01), and at the same time increased contrast sensitivity at both three and six cycles per degree (each p<0.05). Neither of these variables changed significantly in the control group. Dorzolamide also accelerated retinal arteriovenous passage time of fluorescein dye, at constant retinal arterial and venous diameters (p<0.05), but failed to change flow velocities in any retrobulbar vessel. The ability of dorzolamide to improve contrast sensitivity in persons with normal-tension glaucoma may be related to either IOP reduction or altered ocular perfusion.",
author = "Alon Harris and Oliver Arend and Larry Kagemann and Melanie Garrett and Chung, {Hak Sung} and Bruce Martin",
year = "1999",
month = "6",
language = "English",
volume = "15",
pages = "189--197",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma

AU - Harris, Alon

AU - Arend, Oliver

AU - Kagemann, Larry

AU - Garrett, Melanie

AU - Chung, Hak Sung

AU - Martin, Bruce

PY - 1999/6

Y1 - 1999/6

N2 - The purpose of this study was to determine how a topical carbonic anhydrase inhibitor, dorzolamide, alters visual function and ocular blood flow in persons with normal-tension glaucoma. Eighteen normal tension glaucoma patients, after washout of other ocular medications, were treated for four weeks with 2% dorzolamide, three times daily. A control group of eleven other normal-tension glaucoma patients received placebo eye drops. Patients were studied before treatment, and after two and four weeks of treatment. Each study included assessment of central visual function (contrast sensitivity), intraocular pressure (IOP), and several aspects of ocular hemodynamics, including measures of retinal arteriovenous passage time, retinal arterial and venous diameters, and flow velocities in the ophthalmic, central retinal, and posterior ciliary arteries. Dorzolamide significantly reduced lOP at two and four weeks (each p<0.01), and at the same time increased contrast sensitivity at both three and six cycles per degree (each p<0.05). Neither of these variables changed significantly in the control group. Dorzolamide also accelerated retinal arteriovenous passage time of fluorescein dye, at constant retinal arterial and venous diameters (p<0.05), but failed to change flow velocities in any retrobulbar vessel. The ability of dorzolamide to improve contrast sensitivity in persons with normal-tension glaucoma may be related to either IOP reduction or altered ocular perfusion.

AB - The purpose of this study was to determine how a topical carbonic anhydrase inhibitor, dorzolamide, alters visual function and ocular blood flow in persons with normal-tension glaucoma. Eighteen normal tension glaucoma patients, after washout of other ocular medications, were treated for four weeks with 2% dorzolamide, three times daily. A control group of eleven other normal-tension glaucoma patients received placebo eye drops. Patients were studied before treatment, and after two and four weeks of treatment. Each study included assessment of central visual function (contrast sensitivity), intraocular pressure (IOP), and several aspects of ocular hemodynamics, including measures of retinal arteriovenous passage time, retinal arterial and venous diameters, and flow velocities in the ophthalmic, central retinal, and posterior ciliary arteries. Dorzolamide significantly reduced lOP at two and four weeks (each p<0.01), and at the same time increased contrast sensitivity at both three and six cycles per degree (each p<0.05). Neither of these variables changed significantly in the control group. Dorzolamide also accelerated retinal arteriovenous passage time of fluorescein dye, at constant retinal arterial and venous diameters (p<0.05), but failed to change flow velocities in any retrobulbar vessel. The ability of dorzolamide to improve contrast sensitivity in persons with normal-tension glaucoma may be related to either IOP reduction or altered ocular perfusion.

UR - http://www.scopus.com/inward/record.url?scp=0032983212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032983212&partnerID=8YFLogxK

M3 - Article

C2 - 10385127

AN - SCOPUS:0032983212

VL - 15

SP - 189

EP - 197

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -